Polymorphisms in polycyclic aromatic hydrocarbon metabolism and conjugation genes, interactions with smoking and prostate cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 4, 2006, Pages 756-761

  Nock, Nora L ^a   Liu, Xin ^c   Cicek, Mine S ^d   Li, Li ^b   Macarie, Flavius ^d   Rybicki, Benjamin A ^e   Plummer, Sarah J ^d   MacLennan, Gregory T ^a   Casey, Graham ^d   Witte, John S ^c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CARCINOGEN; CYTOCHROME P450 1A1; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; HISTIDINE; ISOLEUCINE; POLYCYCLIC AROMATIC HYDROCARBON; VALINE;

ADULT; ALLELE; ARTICLE; CANCER RISK; CANCER STAGING; CIGARETTE SMOKING; CONJUGATION; CONTROLLED STUDY; DNA POLYMORPHISM; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLISM; PRIORITY JOURNAL; PROSTATE CANCER;

CASE-CONTROL STUDIES; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYCYCLIC HYDROCARBONS, AROMATIC; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; TOBACCO USE DISORDER;

EID: 33646263609     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0826     Document Type: Article

References (58)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Coughlin SS, Hall IJ. A review of genetic polymorphisms and prostate cancer risk. Ann Epidemiol 2002;12:182-96.
3. Kobrinsky NL, Klug MG, Hokanson PJ, Sjolander DE, Burd L. Impact of smoking on cancer stage at diagnosis. J Clin Oncol 2003;21:907-13.
4. Plaskon LA, Penson DF, Vaugham TL, Stanford JL. Cigarette smoking and risk of prostate cancer in middle-aged men. Cancer Epidemiol Biomark Prev 2003;12:604-9.
5. Hickey K, Do K-A, Green A. Smoking and prostate cancer. Epidemiol Rev 2001;23:115-25.
6. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003;3:733-44.
7. Thakker DR, Yagi H, Levin W, Wood AW, Conney AH, Jerina DM. Polycyclic aromatic hydrocarbons: metabolic activation to ultimate carcinogens. In: Anders MW, editor. Bioactivation of foreign compounds. Orlando (Florida): Academic Press; p. 177-242.
8. Hoffmann D, Hoffmann I, El-Bayoumy K. The less harmful cigarette: a controversial issue. a tribute to Ernst L. Wynder. Chem Res Toxicol 2001;14:767-90.
9. Shimada T, Hayes CL, Yamazaki H, et al. Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. Cancer Res 1996;56:2979-84.
10. Shimada T, Watanabe J, Kawajiri K, et al. Catalytic properties of polymorphic human cyctochrome P450 1B1 variants. Carcinogenesis 1999;20:1607-13.
11. Murata M, Watanabe M, Yamanaka M, et al. Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione-S-transferase (GST) M1 and GSTT1 susceptibility to prostate cancer in the Japanese population. Cancer Lett 2001;165:171-7.
12. Tanaka Y, Sasaki M, Kaneuchi M, Shiina H, Igawa M, Dahiya R. Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem Biophys Res Commun 2002;296:820-6.
13. Suzuki K, Matsui H, Nakazato H, et al. Association of the genetic polymorphism in cytochrome P450 (CYP) 1A1 with risk of familial prostate cancer in a Japanese population: a case-control study. Cancer Lett 2003;195:177-83.
14. Fukatsu T, Hirokawa Y, Araki T, et al. Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population. Anticancer Res 2004;24:2431-7.
15. Cicek MS, Liu X, Casey G, Witte JS. Role of androgen metabolism genes CYP1B1, PSA/KLK3, and CYP11α in prostate cancer risk and aggressiveness. Cancer Epidemiol Biomarkers Prev 2005;14:2173-7.
16. Schwarz D, Kisselev P, Chernogolov A, Schunck WH, Roots I. Human CYP1A1 variants lead to differential eicosapentaenoic acid metabolite patterns. Biochem Biophys Res Commun 2005;336:779-83.
17. Finnstrom N, Bjelfman C, Soderstrom TG, et al. Detection of cytochrome P450 mRNA transcripts in prostate samples by RT-PCR. Eur J Clin Invest 2001;10:880-6.
18. Di Paolo OA, Teitel CH, Nowell S, Coles BF, Kadlubar FF. Expression of cytochromes P450 and glutathione S-transferases in human prostate and the potential for activation of heterocyclic amine carcinogens via acetyl-coA-PAPs and ATP-dependent pathways. Int J Cancer 2005;117:8-13.
19. Ragavan N, Hewitt R, Cooper LJ, et al. CYP1B1 expression in prostate is higher in the peripheral than the transition zone. Cancer Lett 2004;215:69-78.
20. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897-906.
21. Sterling KM, Cutroneo KR. Constitutive and inducible expression of cytochromes P4501A (CYP1A1 and CYP1A2) in normal prostate and prostate cancer cells. J Cell Biochem 2004;91:423-9.
22. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 1994;3:421-8.
23. Hassett C, Lin J, Carty CL, Laurenzana EM, Omiecinski CJ. Human hepatic microsomal epoxide hydrolase: a comparative analysis polymorphic expression. Arch Biochem Biophys 1997;337:275-83.
24. Murray GI, Taylor VE, McKay JA, et al. The immunohistochemical localization of drug- metabolizing enzymes in prostate cancer. J Pathol 1995;177:147-52.
25. Pang ST, Dillner K, Wu X, Pousette A, Norstedt G, Flores-Morales A. Gene expression profiling of androgen deficiency predicts a pathway of prostate apoptosis that involves genes related to oxidative stress. Endocrinology 2002;143:4897-906.
26. Lee WJ, Brennan P, Boffetta P, et al. Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. Biomarkers 2002;7:230-41.
27. Huang WY, Chatterjee N, Chancock S, et al. Microsomal epoxide hydrolase polymorphisms and risk for advanced colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2005;14:152-7.
28. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005;45:51-88.
29. Lee WH, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the π-class glutathione S-transferase gene accompanies human prostatic Carcinogenesis. Proc Natl Acad Sci U S A 1994;91:11733-7.
30. Sundberg K, Widersten M, Seidel A, Mannervik B, Jernstrom B. Glutathione conjugation of bay- and fjord-region diol epoxides of polycyclic aromatic hydrocarbons by glutathione transferases M1-1 and P1-1. Chem Res Toxicol 1997;10:1221-7.
31. Chetcuti A, Margan S, Mann S, et al. Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array. Prostate 2001;47:132-40.
32. Elek J, Park KH, Narayanan R. Microarray-based expression profiling in prostate tumors. In Vivo 2000;14:173-82.
33. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase π locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997;18:641-4.
34. Steinhoff C, Franke KH, Golka K, et al. Glutathione transferase isozyme genotypes in patients with prostate and bladder carcinoma. Arch Toxicol 2000;74:521-6.
35. Kote-Jarai Z, Easton D, Edwards SM, et al. Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. Pharmacogenetics 2001;11:325-30.
36. Acevedo C, Opazo JL, Huidobro C, et al. Positive correlation between single or combined genotypes of CYP1A1 and GSTM1 in relation to prostate cancer in Chilean people. Prostate 2003;57:111-7.
37. Rebbeck TR, Walker AH, Jaffe JM, White DL, Wein AJ, Malkowicz SB. Glutathione S-transferase-μ (GSTM1) and -θ (GSTT1) genotypes in the etiology of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999;8:283-7.
38. Gsur A, Haidinger G, Hinteregger S, et al. Polymorphisms of glutathione S-transferase genes (GSTP1, GSTM1 and GSTT1) and prostate cancer risk. Int J Cancer 2001;95:152-5.
39. Kidd LC, Woodson K, Taylor PR, Albanes D, Virtamo J, Tangrea JA. Polymorphisms in glutathione-S-transferase genes (GST-M1, GST-T1 and GST-P1) and susceptibility to prostate cancer among male smokers of the ATBC cancer prevention study. Eur J Cancer Prev 2003;12:317-20.
40. Plummer SJ, Conti DV, Paris PL, Curran AP, Casey G, Witte JS. CYP3A4 and CYP3A5 genotypes, haplotypes and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12:928-32.
41. Welfare M, Monesola AA, Bassendine MF, Daly AK. Polymorphisms in GSTP1, GSTM1 and GSTT1 and susceptibility to colorectal cancer. Cancer Epidemiol Biomarkers Prev 1999;8:289-92.
42. Arand M, Muhlbauer R, Hengstler J, et al. A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms. Anal Biochem 1996;236:184-6.
43. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989;84:1074-8.
44. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998;90:1225-9.
45. Agalliu I, Langeberg WJ, Lampe JW, Salinas CA, Stanford JL. Glutathione S-transferase M1, T1, and P1 polymorphisms and prostate cancer risk in middle-aged men. Prostate 2006;66:146-56.
46. Kelada SN, Kardia SL, Walker AH, Wein AJ, Malkowicz SB, Rebbeck TR. The glutathione S-transferase and in the etiology of prostate cancer: genotype-environment interactions with smoking. Cancer Epidemiol Biomarkers Prev 2000;9:1329-34.
47. Sundberg K, Dreij K, Seidel A, Jernstrom B. Glutathione conjugation and DNA adduct formation of dibenzo(a,l)pyrene and benzo(a)pyrene diol epoxides in v79 cells stably expressing different human glutathione transferases. Chem Res Toxicol 2002;15:170-9.
48. van Bladeren PJ. Glutathione conjugation as a bioactivation reaction. Chem Biol Interact 2000;129:61-76.
49. Bruning T, Lammert M, Kempkes M, Thier R, Golka K, Bolt HM. Influence of polymorphisms of GSTM1 and GSTT1 for risk of renal cell cancer in workers with long-term high occupational exposure to trichloroethene. Arch Toxicol 1997;71:596-9.
50. Antilla A, Pukkala E, Sallmen M, Hernberg S, Hemminki K. Cancer incidence among Finnish workers exposed to halogenated hydrocarbons. J Occup Environ Med 1995;37:797-806.
51. Morgan RW, Kelsh MA, Zhao K, Heringer S. Mortality of aerospace workers exposed to trichloroethylene. Epidemiology 1998;9:424-31.
52. Mukherjee SB, Aravinda S, Gopalakrishnan B, Nagpal S, Salunke DM, Shaha C. Secretion of glutathione S-transferase isoforms in the seminiferous tubular fluid, tissue distribution and sex steroid binding by rat GSTM1. Biochem J 1999;340:309-20.
53. Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005;14:2257-60.
54. Bogaards JJ, Vanekamp JC, van Blderen PJ. Stereoselective conjugation of prostaglandin A2 and prostaglandin J2 with glutathione catalyzed by the human glutathione-S-transferases A1-1, A2-2, M1-1a and P1-1. Chem Res Toxicol 1997;10:310-7.
55. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol 2004;171:S36-40.
56. Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN, Stock RG. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int 2005;95:961-2.
57. Witte JS, Gauderman WJ, Thomas DC. Asymptotic bias and efficiency in case-control studies of candidate genes and gene-environment interactions: basic family designs. Am J Epidemiol 1999;149:693-705.
58. Cortessis V, Thomas DC. Toxicokinetic genetics: an approach to gene-environment and gene-gene interactions. In: Bird P, Bofetta P, Buffer P, Rice J, editors. Complex metabolic pathways: mechanistic considerations in the molecular epidemiology of cancer. Lyons (France): IARC Scientific Publications; 2004. p. 127-50.